Mingke Pharmaceutical (688373.SH) issued a profit warning, expecting a net loss of about 480 million to 440 million yuan in 2024, with the loss expanding.

Allie Pharmaceutical (688373.SH) released its annual performance forecast for 2024, with the company expecting a net loss attributable to the owners of the parent company of approximately 4.4 billion to 4.8 billion yuan, an increase in the loss; it is expected that the net loss after deducting non-recurring gains and losses attributable to the owners of the parent company in 2024 will be approximately 4.6 billion to 5 billion yuan, an expansion of the loss.